OP \$140.00 640254

ETAS ID: TM680521

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

SUBMISSION TYPE: NEW ASSIGNMENT

NATURE OF CONVEYANCE: NOTICE OF GRANT OF SECURITY INTEREST IN TRADEMARKS

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
RVL PHARMACEUTICALS, INC.		10/12/2021	Corporation: DELAWARE

RECEIVING PARTY DATA

Name:	ATHYRIUM OPPORTUNITIES IV ACQUISITION LP, as Administrative Agent
Street Address:	505 Fifth Avenue
Internal Address:	Floor 18
City:	New York
State/Country:	NEW YORK
Postal Code:	10017
Entity Type:	Limited Partnership: DELAWARE

PROPERTY NUMBERS Total: 5

Property Type	Number	Word Mark
Registration Number:	6402543	UPNEEQ
Registration Number:	6336843	UPNEEQ
Registration Number:	6207415	UPNEEQ
Serial Number:	90314754	U
Serial Number:	90281158	UPNEEQ

CORRESPONDENCE DATA

Fax Number: 7043311159

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 7043311000

Email: PTO_TMconfirmation@mvalaw.com,

maryelizabethzaldivar@mvalaw.com

Correspondent Name: Moore & Van Allen PLLC Address Line 1: 100 North Tryon Street

Address Line 2: Suite 4700, ATTN: IP DEPARTMENT Address Line 4: Charlotte, NORTH CAROLINA 28202

ATTORNEY DOCKET NUMBER:	036251.000226
NAME OF SUBMITTER:	John Slaughter

SIGNATURE:	/john slaughter/
DATE SIGNED:	10/12/2021

Total Attachments: 4

source=NGSI-T - RVL Pharmaceuticals, Inc. to Athyrium Opportunities IV Acquisition LP, as Administrative Agent#page1.tif

source=NGSI-T - RVL Pharmaceuticals, Inc. to Athyrium Opportunities IV Acquisition LP, as Administrative Agent#page2.tif

source=NGSI-T - RVL Pharmaceuticals, Inc. to Athyrium Opportunities IV Acquisition LP, as Administrative Agent#page3.tif

source=NGSI-T - RVL Pharmaceuticals, Inc. to Athyrium Opportunities IV Acquisition LP, as Administrative Agent#page4.tif

NOTICE

OF

GRANT OF SECURITY INTEREST

IN

TRADEMARKS

United States Patent and Trademark Office

Ladies and Gentlemen:

Please be advised that pursuant to the Security Agreement dated as of October 12, 2021 (as the same may be amended, modified, restated or supplemented from time to time, the "Security Agreement") by and among the Grantors party thereto (each a "Grantor" and collectively, the "Grantors") and Athyrium Opportunities IV Acquisition LP, as Administrative Agent (the "Administrative Agent") for the Secured Parties referenced therein, the undersigned Grantor has granted a continuing security interest in and continuing lien upon, the trademarks, trademark licenses and trademark applications set forth on Schedule 1 attached hereto to the Administrative Agent for the ratable benefit of the Secured Parties, excluding, for the purposes of this paragraph, any intent-to-use trademark application filed prior to the filing of a "Statement of Use" or "Amendment to Allege Use" with respect thereto, to the extent that, and solely during the period, if any, in which, the grant of a security interest therein would impair the validity or enforceability of such intent-to-use trademark application under applicable law.

The undersigned Grantor and the Administrative Agent, on behalf of the Secured Parties, hereby acknowledge and agree that the security interest in the trademarks, trademark licenses and trademark applications granted herein (i) may only be terminated in accordance with the terms of the Security Agreement, (ii) is not to be construed as an assignment of any trademark, trademark license or trademark application.

[Signature pages follow]

Block DocID

Very truly yours,

RVL PHARMACEUTICALS, INC.

By: Name: Brian Markison

Title: Chief Executive Officer

OSMOTICA PHARMACEUTICAL CORPNOTICE OF GRANT OF SECRITY INTEREST IN TRADEMARKS

Acknowledged and Accepted:

ADMINISTRATIVE AGENT:

ATHYRIUM OPPORTUNITIES IV ACQUISITION LP, a Delaware limited partnership

By: ATHYRIUM OPPORTUNITIES ASSOCIATES IV LP, its General Partner

By: ATHYRIUM OPPORTUNITIES ASSOCIATES IV GP LLC, the General Partner of Athyrium Opportunities Associates IV LP

By: Rashida Adams

Name: Rashida Adams

Title: Authorized Signatory

Schedule 1

RVL Pharmaceuticals, Inc. (Delaware Corporation)

U.S. Trademarks

Trademark Registrations

Mark	Reg. No.	Reg. Date
UPNEEQ	6402543	06/29/2021
UPNEEQ and Design	6336843	04/27/2021
UPNEEQ	6207415	11/24/2020

Trademark Applications

Mark	Appl. No.	Filing Date
U and Design	90314754	11/12/2020
UPNEEQ and Design	90281158	10/27/2020

Block DocID

RECORDED: 10/12/2021